A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Spironolactone Oral Suspension in Pediatric Patients
Phase 4
Not yet recruiting
- Conditions
- Edema Due to Heart Failure or Cirrhosis
- Interventions
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- CMP Development, LLC
- Target Recruit Count
- 96
- Registration Number
- NCT06021860
Drug-drug Interaction (DDI) Study of Spironolactone (Perpetrator) and Digoxin (Substrate Drug)
Phase 1
Completed
- Conditions
- Drug Drug Interaction
- Interventions
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- CMP Development, LLC
- Target Recruit Count
- 28
- Registration Number
- NCT03909529
- Locations
- 🇮🇳
ClinSync Clinical Research Pvt. Ltd., Hyderabad,, Telangana, India
© Copyright 2025. All Rights Reserved by MedPath